Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CABA

Cabaletta Bio, Inc.

Healthcare | Biotechnology

No licensed closing price on file for CABA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Cabaletta Bio, Inc. (NASDAQ: CABA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-11-02 20:50 UTC.

What Cabaletta Bio, Inc. does

Cabaletta Bio is a late-stage biotechnology company developing engineered T cell therapies for autoimmune diseases using its CABA platform, which focuses on the CARTA approach—Chimeric Antigen Receptor T cells designed to reset the immune system. The company's lead product candidate, rese-cel, is engineered to deplete B cells following a single infusion and allows for repopulation by healthy B cells, potentially providing durable responses without chronic therapy.

Summarized from Cabaletta Bio, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for CABA are available in Oxford Ledge.
Open CABA in Oxford Ledge →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-10
Most recent filed transactions — June 2026:
  • 2026-06-10DirectorStock Option (Right to Buy)Award22,000—
  • 2026-06-10DirectorStock Option (Right to Buy)Award22,000—
  • 2026-06-10DirectorStock Option (Right to Buy)Award22,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →
For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CABA and 5,000+ tickers.

Create a free account — keep CABA
For your agent
GET /api/data?ticker=CABA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt